

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Eric K. Steffe Michael Q. Lee Robert C Millonic Donald J. Featherston Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit

Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Jason D. Eisenberg Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Helene C. Carlson Cynthia M. Bouchez limothy A. Doyle Gaby L. Longsworth Lori A. Gordon

July 2, 2008

Laura A. Vogel Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz lohn T. Haran Carla Ji-Eun Kim Doyle A. Siever\* Ulrike Winkler Jenks C. Matthew Rozier Shameek Ghose

Randall K. Baldwin Kandall K. Baldwin Daniel J. Nevrivy Lori M. Brandes Jeffrey K. Mills\* Mita Mukherjee\* Soott M. Woodhouse\* Christian A. Camarce\* Richard D. Coller III\* Bonnie Nannenga-Combs Alyssa K. Sandrowitz\* Ishan P. Weerakoon\*

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Peter A. Socarras Danielle L. Letting

Steven C. Oppenheimer Aaron S. Lukas

\*Admitted only in Maryland \*Admitted only in Virginia •Practice Limited to

WRITER'S DIRECT NUMBER: (202) 772-8525 INTERNET ADDRESS: BRIAND@SKGF.COM

Art Unit 1648

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

Attn: Mail Stop Certificate of Correction Branch

U.S. Patent No. 7,279,165; Issued: October 9, 2007

Amyloid B1-6 Antigen Arrays

Inventors: BACHMANN et al. Our Ref: 1700.0350002/BJD/GAL

Sir:

Certificate
Of Correction Transmitted herewith for appropriate action are the following documents:

1. Request for Certificate of Correction Under 37 C.F.R. § 1.322;

2. Certificate of Correction (PTO/SB/44);

- 3. A copy of the Notice of Recordation of Assignment recorded January 23, 2004, corresponding to reel/frame 014280/0677;
- 4. A copy of the Official Filing Receipt dated March 29, 2004; and
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Attorney for Patentee Cytos Biotechnology AGEIVED-USPTO

Registration No. 42,473

JUL - 7 2008

841408 1.DOC

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

BJD/GAL/lam **Enclosures** 



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

Confirmation No.: 5998

BACHMANN et al.

Art Unit: 1648

Patent. No.: 7,279,165 B2

Examiner: Horning, Michelle S.

Issued: October 9, 2007

Atty. Docket: 1700.0350002/BJD/GAL

Amyloid β1-6 Antigen

**Arrays** 

## Request for Certificate of Correction Under 37 C.F.R. § 1.322

Attn: Certificate of Correction Branch

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

It is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-captioned United States Patent. This Certificate of Correction is being requested due to mistakes which appear in the printed patent. These mistakes were made by the U.S. Patent and Trademark Office.

Specifically, the printed patent contains the following error for which a Certificate of Correction is respectfully requested:

On the face page, first column, section (73), please delete "Cytos Biotechnology AG, Zurich-Schlieren (CH)", and insert therein -- Cytos Biotechnology AG, Zurich-Schlieren (CH); Novartis Pharma AG, Basel, Switzerland (CH) --. While Patentees are aware that the only Assignee listed on the Issue Fee Transmittal Form in section 3 entitled, "Assignee Name and Residence Data to be Printed on the Patent," is Cytos Biotechnology AG, Patentees believe that there is sufficient support for the need for correction of this error to be considered to be an Office Mistake. Specifically Patentees note that according to the records of the Assignment Branch of the USPTO, the present JUL - 7 2008 patent was assigned to the assignee not designated as such on the face page of the issued patent (*i.e.*, Novartis Pharma AG) during the pendency of the application that resulted in the captioned patent, as reflected in the Notice of Recordation of Assignment recorded January 23, 2004, corresponding to reel/frame no. 014280/0677; whereby inventors, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, and Peter Frey assigned their rights to Novartis Pharma AG. Additional support can be found on the Official Filing Receipt dated March 29, 2004. Copies of both the Notice of Recordation and the Official Filing Receipt are provided herewith.

## Remarks

The above-noted corrections do not involve such changes in the patent as would constitute new matter or would require reexamination.

A completed Form PTO/SB/44 accompanies this request, with the above-noted corrections printed thereon. Accordingly, a Certificate of Correction is believed proper and issuance thereof is respectfully requested.

If Patentee's foregoing comments do not satisfy the requirements set forth under 37 C.F.R. § 1.322, then the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono

Attorney for Patentee Cytos Biotechnology AG

Registration No. 42,473

Date: July 2, 2008

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

835784 1.DOC

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number (Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO: 7,279,165

DATED:

October 9, 2007

INVENTOR(S): BACHMANN et al.

It is certified that error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

On the face page, first column, section (73), please delete "Cytos Biotechnology AG, Zurich-Schlieren (CH)", and insert therein -- Cytos Biotechnology AG, Zurich-Schlieren (CH); Novartis Pharma AG, Basel, Switzerland (CH) --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

1100 New York Avenue, NW Washington DC 20005-3934

Atty. Dkt. No. 1700.0350002/BJD/GAL

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. rulliation





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231



JANUARY 23, 2004

PTAS STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005

> UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/23/2004

REEL/FRAME: 014280/0677

NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ORTMANN, RAINER

DOC DATE: 01/06/2004

ASSIGNOR:

LUOND, RAINER

DOC DATE: 12/12/2003

ASSIGNOR:

STAUFENBIEL, MATTHIAS

DOC DATE: 12/15/2003

ASSIGNOR:

FREY, PETER

DOC DATE: 12/12/2003

ASSIGNEE:

NOVARTIS PHARMA AG LICHTSTRASSE 35 BASEL, SWITZERLAND CH-4002

> RECEIVED-USPTO rulum Publication

> > JUL - 7 2008

OPR/ASSIGNMENTS

23/04 2:10 PAGE 3/4 Rig. FAX

014280/0677 PAGE 2

SERIAL NUMBER: 10622087

PATENT NUMBER:

FILING DATE: 07/18/2003

ISSUE DATE:

SHAREILL COLES, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

PLICE VED VEDTO

JUL - 7 2008



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO. Doz. 1450 Alexandria, Viginia 22313-1450 www.mphu.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/622,087	07/18/2003	1645	1784	1700.0350002/BJD/SJE	23	51	1

26111 STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005 CONFIRMATION NO. 5998
UPDATED FILING RECEIPT
\*OC000000012204619\*

Date Mailed: 03/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Martin F. Bachmann, Seuzach, SWITZERLAND; Alain Tissot, Zurich, SWITZERLAND; Rainer Ortmann, Saint Louis, FRANCE; Rainer Luond, Therwil, SWITZERLAND; Matthias Staufenbiel, Lorrach, GERMANY; Peter Frey, Bern, SWITZERLAND;

**Assignment For Published Patent Application** 

Cytos Biotechnology AG; Novartis Pharma AG;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/470,432 05/15/2003 and claims benefit of 60/396,639 07/19/2002

Foreign Applications

If Required, Foreign Filing License Granted: 10/17/2003

Projected Publication Date: 07/08/2004

Non-Publication Request: No

Early Publication Request: No

MAR 3 0 2004 Mar 1 1947 (1972)

B√D 03 → 6

Ne 8/31

RECEIVED-USPTO

JUL - 7 2008

Title

Amyloid beta 1-6 antigen arrays

**Preliminary Class** 

424

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

